In an 86-year-old woman in long-term care receiving duloxetine 30 mg twice daily and levetiracetam for seizures, should any additional pharmacologic mood-stabilizing agent be added?

No Additional Mood Stabilizer Should Be Added

In this 86-year-old woman in long-term care, you should NOT add another pharmacologic mood-stabilizing agent. Instead, you should strongly consider deprescribing or reducing the duloxetine, as the current regimen itself may be contributing to mood disturbances through levetiracetam's known psychiatric adverse effects.

The Core Problem: Levetiracetam's Psychiatric Effects

Levetiracetam carries significant risk for mood and behavioral disturbances that may be mistaken for primary mood disorders requiring additional treatment:

• Non-psychotic mood disorders (depression, depressed mood, mood swings) occur in 6.7-12.7% of patients on levetiracetam versus 3.3-8.3% on placebo 1
• Behavioral disorders (aggression, irritability) occur in 5-11.4% of levetiracetam patients 1
• In elderly patients specifically, levetiracetam has been documented to cause new-onset depression that resolves upon discontinuation 2
• The elderly are at higher risk for these psychiatric effects, particularly those with renal impairment (common in this age group), as levetiracetam clearance decreases by 70% in end-stage renal disease 1

Why Adding a Mood Stabilizer Is the Wrong Approach

The Polypharmacy Trap

This 86-year-old is already on duloxetine 30 mg twice daily (60 mg total daily) plus levetiracetam. Adding a third psychoactive medication creates:

• Increased anticholinergic burden if using agents like valproate or carbamazepine, which is associated with cognitive decline, functional impairment, falls, and decreased ADL scores in elderly patients 3
• Drug-drug interactions that complicate management
• Higher risk of adverse events - the very problem you're trying to solve

The 2021 Mayo Clinic guidelines on polypharmacy management emphasize that in long-term care residents, deprescribing should be the primary strategy, particularly targeting medications that may be causing the symptoms you're attempting to treat 3.

The Correct Clinical Algorithm

Step 1: Assess Renal Function

• Check creatinine clearance immediately
• If CrCl <80 mL/min, levetiracetam dosing should be reduced 1
• Levetiracetam clearance decreases by 40% (mild), 50% (moderate), or 60% (severe renal impairment) 1

Step 2: Evaluate the Temporal Relationship

• When did mood symptoms begin relative to levetiracetam initiation?
• Case reports show mood symptoms emerging within 5 weeks to 5 months of starting levetiracetam, with resolution within 4-8 days of discontinuation 2

Step 3: Consider Deprescribing Strategy

Option A - If seizure control allows:

• Taper levetiracetam gradually to minimize withdrawal seizure risk 1
• Monitor for mood improvement over 1-2 weeks

Option B - If levetiracetam must continue:

• Reduce levetiracetam dose based on renal function 1
• Consider reducing or discontinuing duloxetine (see below)

Step 4: Reassess Duloxetine Necessity

At 86 years old in long-term care, duloxetine may not be appropriate:

• Discontinuation rates due to adverse effects are higher with duloxetine than SSRIs (67% increased risk vs. SSRIs as a class) 4
• Preferred antidepressants in elderly include citalopram, escitalopram, sertraline, mirtazapine, venlafaxine, or bupropion 4
• Duloxetine 60 mg daily was studied in elderly depression, but this patient is in long-term care where functional status and medication burden are critical 5

Critical Pitfalls to Avoid

1. Mistaking drug-induced mood symptoms for primary mood disorder - This leads to prescribing cascades where you treat side effects with additional medications
2. Ignoring renal function - Levetiracetam accumulation in renal impairment dramatically increases psychiatric side effects 2
3. Assuming higher doses are needed - The evidence shows levetiracetam psychiatric effects are dose-related; reduction may resolve symptoms 1
4. Adding valproate or carbamazepine - These traditional mood stabilizers have significant anticholinergic burden and drug interactions, particularly problematic in elderly long-term care residents 3

If Mood Stabilization Is Truly Needed After Optimization

Only after optimizing the current regimen and confirming a primary mood disorder should you consider:

• First-line: Optimize or switch antidepressant to a preferred elderly agent (escitalopram, sertraline) 4
• Avoid: Traditional mood stabilizers (valproate, carbamazepine) due to anticholinergic burden in this population 3
• Lamotrigine has the most favorable evidence among anticonvulsants for mood, but requires slow titration and monitoring

The answer to "anything else to add" is: subtract first, don't add. 3, 1, 2